Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: A multicenter, open-labeled, single-arm phase II trial

被引：0
|
作者：
Zhuang, Junlong
Wang, Yuwen
Zhang, Shun
Qiu, Xuefeng
Zhou, Feng
Fu, Yao
Wei, Xuedong
Xu, Linfeng
Guo, Hongqian
机构：
[1] Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Med Sch, Nanjing, Peoples R China
[2] Nanjing Univ, Affiliated Drum Tower Hosp, Med Sch, Dept Urol, Nanjing, Peoples R China
[3] Nanjing Univ, Inst Urol, Nanjing, Peoples R China
[4] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Urol, Hangzhou, Peoples R China
[5] Nanjing Univ, Affiliated Drum Tower Hosp, Med Sch, Dept Pathol, Nanjing, Peoples R China
[6] Soochow Univ, Affiliated Hosp 1, Dept Urol, Suzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.4_suppl.321
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：321 / 321
页数：1
相关论文
共 50 条
  • [1] A single arm, phase I/II trial of neoadjuvant androgen deprivation, darolutamide, and ipatasertib in men with localized, high-risk prostate cancer.
    Vander Weele, David James
    Fenton, Sarah Elizabeth
    Auffenberg, Gregory
    Jovanovic, Borko
    Hussain, Maha H. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [2] Adjuvant androgen-deprivation therapy following prostate total cryoablation in high-risk localized prostate cancer patients - Open-labeled randomized clinical trial
    Chen, Chung-Hsin
    Pu, Yeong-Shiau
    [J]. CRYOBIOLOGY, 2018, 82 : 88 - 92
  • [3] Androgen Deprivation Therapy in High-Risk Prostate Cancer
    Buyyounouski, Mark K.
    [J]. ONCOLOGY-NEW YORK, 2010, 24 (09): : 806 - 809
  • [4] Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer
    Iwamoto, Hiroaki
    Izumi, Kouji
    Makino, Tomoyuki
    Mizokami, Atsushi
    [J]. CANCERS, 2022, 14 (07)
  • [5] Neoadjuvant therapy for high-risk localized prostate cancer
    Evan Y. Yu
    William K. Oh
    [J]. Current Oncology Reports, 2003, 5 (3) : 250 - 257
  • [6] On-target activity of neoadjuvant cixutumumab and combined androgen deprivation therapy for high-risk prostate cancer: A phase II trial
    Dean, J. P.
    Montgomery, R. B.
    Wan, J.
    Cohen, P.
    Haugk, K.
    Corman, J. M.
    Ellis, W. J.
    Dalkin, B. L.
    Ludwig, D. L.
    Plymate, S. R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [7] Impact of therapy on cancer metabolism in high-risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy
    Qu, Feng
    Gu, Yue
    Xue, Mengxia
    He, Mingzhe
    Zhou, Fang
    Wang, Guangji
    Peng, Ying
    [J]. PROSTATE, 2021, 81 (09): : 560 - 571
  • [8] Phase II study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high-risk localized prostate cancer (HRLCaP).
    McKenzie, M. R.
    Chi, K. N.
    Neville, A.
    Ellard, S.
    Baerg, B.
    Ruether, D.
    Winquist, E.
    Segal, R.
    Lukka, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 249S - 249S
  • [9] Neoadjuvant IMC-A12 and combined androgen deprivation with prostatectomy for high-risk prostate cancer: A phase II trial
    Dean, J. P.
    Plymate, S. R.
    Dalkin, B. L.
    Ellis, W. J.
    Lin, D. W.
    Wright, J. L.
    Corman, J. M.
    True, L. D.
    Lange, P. H.
    Montgomery, R. B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Neoadjuvant pamiparib plus abiraterone and ADT for high-risk/very high-risk localized prostate cancer: Results of a prospective study
    Zhuang, J.
    Zhang, S.
    Qiu, X.
    Zhou, F.
    Guo, H.
    [J]. EUROPEAN UROLOGY, 2024, 85 : S1532 - S1532
12345